Community participation needed for “Bras for a Cause”

Translate to Spanish or other 102 languages!

Photo Used for Illustration Purposes. Photo by drazenphoto
- Advertisement -

Every October, DHR Health employees tap into their creativity to participate in the hospital’s annual “Bras for a Cause” fundraiser. This event supports underserved cancer patients throughout the Rio Grande Valley by providing vital resources such as transportation assistance, financial aid, and oncology wigs through the Renaissance Cancer Foundation.

This year, nearly 30 decorated bras were submitted by employees from various departments, showcasing their enthusiasm for raising awareness about breast cancer screenings and mammograms.

“We hold this contest every year as a fun and engaging way for our employees to help promote breast cancer awareness,” said Evelyn Saenz, Executive Director of the Renaissance Cancer Foundation. “We’re always so impressed by the many creative entries we receive.”

- Advertisement -

Community members are encouraged to visit www.dhrhealth.com/brasforacause to view photos of the bra entries and cast their votes by making donations. The bras with the highest donation totals will be declared winners of the fundraiser. Voting is open to the community until October 20, 2024.

All donations to the Renaissance Cancer Foundation are tax-deductible and directly support local cancer patients facing financial challenges during their treatment. For more information about the Renaissance Cancer Foundation or how to get involved, please contact Executive Director Evelyn Saenz at ev.saenz@dhr-rgv.com.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

STHS Dedicating Latest “South Texas Healthy Living” Episode to Arthritis Education, July 26th

More than 58 million U.S. adults are living with doctor-diagnosed arthritis, according to the Centers for Disease Control and Prevention (CDC), making it the nation’s leading cause of disability.

No More Needles: FDA Approves First Daily Pill to Replace Injectable Cholesterol Drugs

The U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). Image source: Merck.com.

STHS Heart Ranks Among Nation’s Top Hospitals for Heart Attack Care

Every year, more than 800,000 people in the United States suffer a heart attack, according to the Centers for Disease Control and Prevention, an event that occurs approximately every 40 seconds.

DHR Health Burn Surgeon Urges Public to Avoid Preventable Risks

Many of the most serious burn and trauma injuries can be prevented by avoiding unnecessary risks, according to Dr. R. Dewayne Edwards, chief burn surgeon, surgical critical care and trauma surgeon at DHR Health, who said public awareness and timely medical care remain essential to improving patient outcomes.
- Advertisement -